Better
Pain Management is Possible
Better
Pain Management is Possible
More than 18 million patients have been treated with Pacira non-opioid therapies. We are building on that foundation every day.
Our goal is to expand treatment options and partner across healthcare to make non-opioid therapies the standard, not the exception.
Leading with science
Our commercial portfolio spans postsurgical, chronic, and musculoskeletal pain. Our pipeline includes a gene therapy candidate for knee osteoarthritis.
Patients at the center
Pain affects every part of life. We help patients understand their options and advocate for non-opioid care with their providers.
Mission-driven
Pacira was built on the belief that patients deserve better options. Our team works across science, education and advocacy to make that real.
Science that refuses to settle
Our commercial therapies address postsurgical, chronic, and musculoskeletal pain.
Our investigational pipeline includes PCRX-201, a gene therapy candidate for knee osteoarthritis, and is is poised to transform how we approach osteoarthritis treatment with the goal of helping patients return to normal function.
We remain committed to advancing therapies backed by rigorous, peer-reviewed clinical evidence.
Empowering shared decision-making
Better conversations lead to better care. We equip patients and caregivers with the resources to explore non-opioid options and partner with their providers on a plan built around them.
Partnering to advance access, education, and advocacy
Expanding access to non-opioid options requires working across the full healthcare system, with providers, policymakers, and patient advocates. More than 40 million people now have coverage for post surgical pain therapies and outpatient surgeries through commercial and governmental plans including the NOPAIN act. We are committed to continuing that progress.
Join us in making a difference
Our teams are united by a passion for excellence and a commitment to patients. Here, you can grow your career while making a real impact.